Omniose

Omniose was founded in 2016 based on the pioneering glycoconjugation discoveries of our scientific founders Mario Feldman and Christian Harding through a scientific collaboration that characterized a new class of conjugating enzymes. The research operations were established at BioGenerator Labs in St. Louis and the company was previously known as VaxNewMo. Omniose has been awarded $11.8 million in grants from the US NIAID for use of our platform technology to develop vaccines against Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae. In January 2024, the company announced an exclusive collaboration agreement with AstraZeneca for up to three years to research potential vaccines for bacterial pathogens.